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Community-acquired pneumonia(CAP) continues to be a common
health challenge worldwide. It is the
eighth leading cause of death and affects
5-6 million people in the United States
yearly.1-3 In Medicare patients older than
65 years, the average hospital length of
stay due to CAP is 7 days; 15% of this
time is spent in the intensive care unit
(ICU), and 25% of patients hospitalized
with CAP are admitted to the ICU.4 The
cost of admission for 1 episode of CAP
is estimated to be $9749.4 In addition,
the emergence of strains of Streptococ-
cus pneumoniae that are resistant to oral
antibiotics such as macrolides (40%) and
penicillins (20%) makes it more difficult
for clinicians to effectively manage treat-
ment for patients with CAP.5,6 Thus, find-
ing new agents to treat CAP and reduce
mortality, morbidity, and the associated
hospital admission cost has become a ne-
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OBJECTIVE: To review the pharmacology, chemistry, microbiology, in vitro suscepti-
bility, mechanism of resistance, pharmacokinetics, pharmacodynamics, clinical
efficacy, safety, drug interactions, dosage, and administration of cethromycin, a new
ketolide antibiotic.
DATA SOURCES: Literature was obtained through searching PubMed (1950-
October 2012), International Pharmaceutical Abstracts (1970-October 2012), and
a bibliographic review of published articles. Search terms included cethromycin,
ABT-773, ketolide antibiotic, and community-acquired pneumonia.
STUDY SELECTION AND DATA EXTRACTION: All available in vitro and preclinical
studies, as well as Phase 1, 2, and 3 clinical studies published in English were
evaluated to summarize the pharmacology, chemistry, microbiology, efficacy, and
safety of cethromycin in the treatment of respiratory tract infections.
DATA SYNTHESIS: Cethromycin, a new ketolide, has a similar mechanism of action
to telithromycin with an apparently better safety profile. Cethromycin displays in vitro
activity against selected gram-positive, gram-negative, and atypical bacteria. The
proposed indication of cethromycin is treatment of mild to moderate community-
acquired bacterial pneumonia in patients aged 18 years or older. Based on clinical
studies, the recommended dose is 300 mg orally once a day without regard to
meals. Cethromycin has an orphan drug designation for tularemia, plague, and
anthrax prophylaxis. The Food and Drug Administration denied approval for the
treatment of community-acquired pneumonia in 2009; a recent noninferiority trial
showed comparable efficacy between cethromycin and clarithromycin. Preliminary
data on adverse effects suggest that cethromycin is safe and gastrointestinal
adverse effects appear to be dose-related. 
CONCLUSIONS: Cethromycin appears to be a promising ketolide for the treatment
of mild to moderate community-acquired pneumonia. It was denied approval by
the FDA in 2009 pending more evidence to show its efficacy, with more recent
studies showing its noninferiority to antibiotics for the same indication.  
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cessity. Cethromycin appears to address the resistance is-
sue by providing adequate coverage against S. pneumoniae
for the treatment of mild to moderate CAP.7 It is a ketolide
antibiotic related to macrolides and is similar to
telithromycin, which is currently the only approved ke-
tolide. Telithromycin was originally approved for the treat-
ment of acute sinusitis and acute exacerbation of chronic
bronchitis in addition to CAP. However, because of con-
cerns regarding hepatotoxicity, exacerbation of myasthenia
gravis, visual disturbances, and loss of consciousness, the
Food and Drug Administration (FDA) narrowed its indica-
tion to treatment of mild to moderate CAP only and added
a black box warning contraindicating its use in myasthenia
gravis. Fortunately, cethromycin does not appear to share
the toxicity profile of telithromycin. The proposed indica-
tion for cethromycin is treatment of mild to moderate com-
munity-acquired bacterial pneumonia (CABP) due to sus-
ceptible strains of S. pneumoniae, Haemophilus influenzae,
Staphylococcus aureus, Moraxella catarrhalis, and Le-
gionella pneumophila in patients aged 18 years or older.8-12 
The development of cethromycin began in 1997 when
Abbott Laboratories, in collaboration with Taisho Pharma-
ceuticals, initiated the investigational process.13 Phase 3 stud-
ies started in 2001 with these 2 laboratories, and Advanced
Life Sciences continued the investigational process in 2005.
Advanced Life Sciences named the drug Restanza and com-
pleted Phase 3 trials for the treatment of CAP and for the
prevention of postexposure inhalation of anthrax. A New
Drug Application was submitted to the FDA on September
30, 2008, seeking approval for use of cethromycin in treat-
ment of mild to moderate CAP. In 2009, the FDA’s Anti-In-
fective Drugs Advisory Committee voted in favor of the
cethromycin safety profile but against its efficacy for treat-
ment of CAP. The FDA has designated it as an orphan drug
for the prophylactic treatment of inhalation anthrax postex-
posure.14,15 In 2011, Advanced Life Sciences declared its liq-
uidation and has been searching for additional investments
in the cethromycin development program.16 The patent for
cethromycin will expire in 2016.13 Despite the freeze in the
approval process for mild to moderate pneumonia, studies
continued to compare cethromycin to drugs marketed for the
treatment of CAP, such as clarithromycin, and to study the
efficacy of cethromycin against non–CAP-related
pathogens.17,18 A recently published study showed an in-
crease in cardiovascular deaths in patients receiving
azithromycin, which is used  frequently for the treatment of
pneumonia.19 Under these circumstances, the search for new
antiinfective agents directed against pneumonia is more war-
ranted than ever before.
Pharmacology
Cethromycin is a 3-keto,11,12 carbamate derivative of
erythromycin A with an O-6 linked aromatic ring. It binds
strongly to the 50S ribosomal subunit and inhibits bacterial
protein synthesis.20 It binds specifically to the 23S riboso-
mal RNA (rRNA) of the 50S ribosomal subunit.21,22 As a
ketolide, cethromycin has affinity to domains II and V of
the 23S rRNA, unlike macrolides that have affinity to do-
main V.23 Since the wall of the polypeptide exit tunnel is
built mainly from nucleotides of domains I through V of
the 23S rRNA, this binding blocks the exit tunnel and pre-
vents the departure of the nascent polypeptide halting pro-
tein synthesis.22 As a ketolide, and similar to erythromycin,
clarithromycin, and azithromycin, cethromycin interacts
with the large ribosomal subunit through hydrophobic in-
teractions of the lactone ring and hydrogen bonding of its
sugar moiety with the ribosome.22 Also, these compounds
can interact with ribosomes that possess short or vacant
chains without touching ribosomes with large chains.24
Macrolides, azalides, and ketolides possess different abili-
ties to inhibit bacterial protein synthesis by halting the
translation of growing peptide chains. For instance, with
erythromycin, terminated peptide chains contain 6-8
residues, whereas, with telithromycin, those formed pep-
tide chains contain 9-10 residues.25 Cethromycin is expect-
ed to have the same mechanism of action as telithromy-
cin.26
Chemistry
Cethromycin (Figure 1),27 formerly known as ABT-773,
is a ketolide that possesses a chemical structure similar to
that of macrolides. The macrolides’ basic structure consists
of a large 12- to 16-membered lactone ring with sugar
moieties attached by glycosidic bonds. Azithromycin is a
15-membrane ring, also known as an azalide compound,
with a tertiary amino compound. Ketolides are 14-mem-
bered rings, like erythromycin and clarithromycin, where a
keto group is present at the C3 position of the lactone ring
and an 11,12 carbamate group.28 Cethromycin has a
quinolylallyl side chain at the C6 position of the lactone
ring; telithromycin has an extended alkyl-aryl group that
branches from 11,12 carbamate group.25
Microbiology
In vitro activity of cethromycin against selected organ-
isms is summarized in Table 1.29-45
GRAM-POSITIVE BACTERIA
Cethromycin displays in vitro activity against strepto-
cocci, including strains of S. pneumoniae that are resistant
to penicillins and macrolides.29-33 It was shown to be more
potent than its predecessor telithromycin against macro-
lide-resistant streptococci and more potent than macrolides
and fluoroquinolones against penicillin-resistant strepto-
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cocci.30,32,34 The susceptibility to penicillin was determined
using the broth microdilution method as described by the
Clinical and Laboratory Standards Institute (Table 1).35 Al-
though cethromycin displays in vitro activity against me-
thicillin- and macrolide-susceptible S. aureus, this activity
is greatly diminished in the presence of genes that confer
resistance to clindamycin.30,31 Cethromycin does not seem
to have reliable in vitro activity against enterococci except
strains of Enterococcus faecalis that are susceptible to van-
comycin.31 It also displays in vitro activity against Bacillus
anthracis and was given an orphan status by the FDA in
2007 for the prophylactic treatment of patients exposed to
inhalation anthrax.29
GRAM-NEGATIVE BACTERIA
Cethromycin displays comparable in vitro activity to
azithromycin against respiratory gram-negative organisms
including β-lactamase–producing H. influenzae and M.
catarrhalis.31,33 It was shown to be more potent than ery-
thromycin and clarithromycin but less potent than fluoro-
quinolones against β-lactamase–producing H. influenzae.32
It showed similar potency against β-lactamase–producing
M. catarrhalis.32 In addition, cethromycin possesses in vit-
ro activity against Francisella tularensis and Yersinia
pestis and was given orphan drug status by the FDA in
2009 for the prophylactic treatment of plague and tu-
laremia.29,36
ATYPICAL AND ANAEROBIC BACTERIA
Cethromycin is active against the 3 organisms common-
ly associated with atypical pneumonia: Chlamydophila spp.,
Legionella spp., and Mycoplasma spp.37-41 It was shown to be
more potent than telithromycin and the macrolides against
Chlamydophila pneumoniae.37,39 The intracellular activity of
cethromycin against L. pneumophila serogroup 1 was greater
than that of macrolides but lower than that of fluoro-
quinolones.40 The activity of cethromycin was comparable to
that of macrolides but greater than that of fluoroquinolones
and doxycycline against Mycoplasma pneumoniae.41 While
cethromycin is active against several anaerobic organisms as-
sociated with sinusitis and bites, it lacks significant activity
against gram-negative anaerobes such as Bacteroides spp.
and Fusobacterium spp.42-45
Resistance
Strains of S. pneumoniae usually develop resistance to
macrolides by either expressing efflux pumps or by alter-
ation of the 50S ribosomal subunit.46,47 The first mecha-
nism of resistance is mediated by the mefA gene and results
in phenotype M.47 It affects only macrolides and is most
prevalent in North America.46 The second mechanism of
resistance is mediated primarily by the ermB gene and oc-
curs after methylation of adenine 2058 in 23S rRNA, re-
sulting in phenotype MLSB. It affects macrolides, lin-
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Figure 1. Chemical structures of related macrolide, azalide, and ketolide antibiotics.26 Permission granted by the American Society for Microbiology through
Copyright Clearance Center’s RightsLink service, August 30, 2012.
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Table 1. In Vitro Activity of Cethromycin
MIC50 MIC90
Organism Isolates, na (µg/mL) (µg/mL)
Gram-positive
Bacillus anthracis29 30 NR 0.12
Staphylococcus aureus
macrolide-susceptible30,31 106 0.008-0.03 0.03
macrolide-resistant30,31 168 0.03 to >32 0.06 to >32
methicillin-susceptible32 180 0.03 0.06
methicillin-resistant32 20 0.06 0.06
Streptococcus agalactiae31 40 0.015 0.015
Streptococcus pneumoniaeb
penicillin-susceptible30,32-34 1501 ≤0.008-0.06 ≤0.01-0.015
penicillin-intermediate30,33,34 441 0.004-0.016 0.008-0.03
penicillin-resistant30,32,33 362 0.004-0.03 0.03-0.125
macrolide-susceptible30,31,34 373 0.001 to ≤0.008 0.002-0.016
macrolide-resistant30,31,34,35 684 0.004-0.063 0.015-0.5
Streptococcus pyogenes
macrolide-susceptible30-32 218 ≤0.002-0.015 ≤0.002-0.015
macrolide-resistant30,31 125 0.002-0.12 0.002-0.5
Gram-negative
Francisella tularensis36 30 NR 1
Haemophilus influenzae
β-lactamase negative31-33 1296 2 4
β-lactamase positive31-33 695 2 4
Moraxella catarrhalis
β-lactamase negative32,33 79 0.03-0.12 0.06-0.12
β-lactamase positive31-33 897 0.03-0.06 0.06-0.12
Neisseria gonorrhoeae31 35 0.03 0.06
Yersinia pestis29 30 NR 2
Atypical
Chlamydophila pneumoniae37-39 53 0.015-0.016 0.015-0.016
Legionella pneumophila40 96 0.03 0.03-0.06
Mycoplasma pneumoniae41 103 ≤0.001 ≤0.001
Ureaplamsa spp.41 24 ≤0.008 0.016
Anaerobes
Bacteroides fragilis42,43 120 2-8 4-8
Bacteroides spp.42 64 0.25-4 4 to >32
Clostridium difficile42 64 0.064-0.125 0.125 to >32
Clostridium perfringens42,43 46 0.032 to ≤0.06 0.032 to ≤0.06
Eikenella corrodens44,45 28 0.5-1 1
Fusobacterium spp.42-45 89 0.25-4 0.5-8
Pasteurella spp.45 62 0.25-1 0.5-1
Peptostreptococcus spp.42-45 180 ≤0.015-0.032 0.03 to ≤0.06
Prevotella spp.42,44,45 73 0.03-0.06 0.06-0.5
Propionibacterium spp.42,43,44 76 0.016 to ≤0.08 0.015 to ≤0.06
Veillonella spp.44 13 1 2
MIC50 = minimum inhibitory concentration for 50% of tested isolates; MIC90 = minimum inhibitory concentration for 90% of tested isolates; NR = not re-
ported.
aReported as mean values. 
bSusceptibility to penicillin was determined using the broth microdilution method as described by the Clinical and Laboratory Standards Institute and
the previously accepted breakpoints of MIC <0.1 µg/mL for susceptible, MIC between 0.1 and 1 µg/mL for intermediate, and MIC >1 µg/mL for re-
sistant. The revised breakpoints for infections other than meningitis are MIC ≤2 µg/mL for susceptible, MIC 4 µg/mL for intermediate, and MIC ≥8
µg/mL for resistant. The revised breakpoints for meningitis are ≤0.06 µg/mL for susceptible and ≥0.12 µg/mL for resistant.
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cosamides, and streptogramins and is most prevalent in
Europe.46 Both mechanisms of resistance have been associ-
ated with clinical failure of treatment in pneumococcal infec-
tions.48,49 The addition of a ketone functional group confers to
ketolides additional protection against resistance by adding a
second ribosomal target site at domains II and V and by in-
creasing the rate and extent of intracellular accumulation,
making it more difficult for bacteria to escape the action of
these antibiotics.46,47 In fact, one study showed that 83% of
the penicillin and erythromycin nonsusceptible isolates were
inhibited by telithromycin and 97% of these isolates were in-
hibited by cethromycin.50 However, rare mutations in 23S
rRNA may result in phenotype K and other rare mutations in
ribosomal protein L4 may result in phenotype MKSB, both of
which affect ketolides.46 For example, strains of phenotype X,
a subgroup of the constitutive MLSB phenotype, have been
shown to be less sensitive to cethromycin compared with oth-
er strains of the inducible MLSB phenotype.51 The mecha-
nisms of resistance of H. influenzae and M. catarrhalis to
macrolides have not been clearly defined, but it is believed
that gram-negative bacteria usually develop resistance to
macrolides by expressing efflux pumps.52 Since ketolides
have a greater affinity to bacterial ribosomes than macrolides,
they retain a more potent activity against these organisms.53
Pharmacokinetics
Plasma pharmacokinetic parameters for cethromycin
administered orally are listed in Table 2.54
ABSORPTION
Steady-state plasma and intrapulmonary pharmacokinet-
ic parameters of cethromycin were determined in healthy
volunteers.54 Five doses of cethromycin 150 or 300 mg
were administered orally once daily to 60 healthy adults.
Cethromycin demonstrated nonlinear pharmacokinetic
properties. It is characterized by relatively low serum con-
centrations, which can be attributed to its large volume of
distribution. Plasma concentrations were not impacted by
the weight of the subjects, with data available only for pa-
tients with a body mass index of 18-29 kg/m2. The coad-
ministration of ranitidine reduces the bioavailability of
cethromycin. One study demonstrated that the maximum
concentration (Cmax) was reduced by 25.7% and the area
under the curve (AUC) was reduced by 15.8%.55 The au-
thors hypothesized that the effect of ranitidine on the
bioavailability of cethromycin may be attributed to its de-
creased solubility at higher gastric pH levels.
DISTRIBUTION 
Cethromycin achieves high intrapulmonary concentra-
tions. For the 24-hour dosing interval in one study, the
mean (SD) epithelial lining fluid concentrations ranged
from 0.9 (1.0) µg/mL at 2 hours (Cmax, time to Cmax [tmax])
to 0.1 (0.1) µg/mL at 24 hours (minimum concentration
[Cmin], time to Cmin [tmin]) for the 150-mg dose group and
from 2.7 (2.0) µg/mL at 4 hours (Cmax, tmax) to 0.1 (0.1)
µg/mL at 24 hours (Cmin, tmin) for the 300-mg dose group.54
Cethromycin alveolar concentrations achieved in this study
ranged from 12.7 (6.4) µg/mL at 8 hours (Cmax, tmax) to 2.9
(2.4) µg/mL at 24 hours (Cmin, tmin) for the 150-mg dose
group and from 55.4 (38.7) µg/mL at 6 hours (Cmax, tmax) to
6.7 (3.4) µg/mL at 24 hours (Cmin, tmin) for the 300-mg
dose group.54 In in vitro studies, cethromycin demonstrated
high penetration into human polymorphonuclear leuko-
cytes, reaching intracellular concentrations several fold
higher than extracellular concentrations.56
METABOLISM 
Cethromycin is metabolized by the liver and a total of 7
metabolites were identified. The major metabolite (M1) was
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Table 2. Cethromycin Pharmacokinetic Parameters for Oral 150- and 300-mg Daily Doses54
Cmax, AUC0-24, Vdss,
Daily Dosea µg/mL tmax, h µg/h/mL t1/2, h mL/kg
150 mg 
Plasma, mean (SD) 0.181 (0.084) 2.01 (1.30) 0.902 (0.469) 4.85 (1.10) 1453 (997)
Epithelial lining fluid 0.94 2.0 11.4 6.43
Alveolar concentration 12.7 8.0 160.8 10.0
300 mg
Plasma, mean (SD) 0.500 (0.168) 2.09 (0.03) 3.067 (1.205) 4.94 (0.66) 769 (272)
Epithelial lining fluid 2.75 4.0 24.15 5.26
Alveolar concentration 55.4 6.0 636.2 11.6
AUC0-24 = area under the concentration-time curve from 0 to 24 hours; Cmax = maximum concentration; t1/2 = elimination half-life; tmax = time to Cmax;
Vdss = volume of distribution at steady-state.
aAdministered as a daily oral dose for 5 days.
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N-desmethyl cethromycin, which accounted for 34.7% of the
administered dose. Other metabolites included a 10-hydroxy
compound and an N-desmethyl-10-hydroxy compound,
which accounted for less than 10% of the administered
dose.57
ELIMINATION 
The primary route of elimination for oral cethromycin is
fecal (average of 87.2%), with 31% of the administered
dose (150 mg) excreted unchanged in the feces. Seven per-
cent of the administered dose is eliminated in the urine, of
which cethromycin accounted for 90% and the remaining
10% was the N-desmethyl metabolite.57 The plasma elimi-
nation half-life (t1/2) of cethromycin 150 mg and 300 mg
after daily administration for 5 days in healthy volunteers,
was 4.85 hours and 4.94 hours, respectively.54
SPECIAL POPULATIONS
Renal Impairment 
The pharmacokinetics of cethromycin in patients with
severe renal impairment were recently studied.29,58 A study
enrolled 10 subjects with normal renal function (creatinine
clearance >80 mL/min) and with stable severe chronic renal
impairment (creatinine clearance 10-29 mL/min). Subjects
received cethromycin 300 mg once daily for 5 days.
Cethromycin’s AUC at 24 hours (AUC24) and the Cmin were
approximately 2.5 times greater in subjects with severe renal
impairment. Similar increases were seen with exposure to
unbound cethromycin. Elevated drug exposure was observed
for subjects with severe renal impairment, which was some-
what unexpected, considering that only approximately 10%
of an oral dose of cethromycin is excreted in urine. No dos-
age adjustment recommendations in patients with severe re-
nal impairment were made in this study.58 Also, cethromycin
was evaluated in individuals with estimated creatinine clear-
ance >80 mL/min and between 10 and 29 mL/min after the
administration of 300-mg dose daily for 5 days. The investi-
gators recommended a dose adjustment of 150 mg daily in
subjects with estimated creatinine clearance between 10 and
29 mL/min; however, those with mild to moderate renal im-
pairment and undergoing dialysis were not studied.29
Hepatic Impairment
The pharmacokinetic properties of cethromycin were
assessed following oral administration to subjects with
mild and moderate chronic hepatic impairment.59 This
study included 12 participants with normal hepatic func-
tion, 6 patients with mild chronic hepatic impairment
(Child-Pugh class A), and 6 patients with moderate chronic
hepatic impairment (Child-Pugh class B). Each subject re-
ceived a single 300-mg dose of cethromycin on study day
1 and 300 mg once daily for 5 days on study days 3-7. No
apparent difference in steady-state exposure was observed
between subjects with mild hepatic impairment or those
with normal hepatic function. However, after 5-day dos-
ing, the AUC24 and Cmin of the total and unbound drug
were greater for participants with moderate hepatic impair-
ment than for those with normal hepatic function. The t1/2
was more prolonged in patients with moderate hepatic im-
pairment compared to those with normal hepatic function
(13.7 vs 9.9 hours, p < 0.05). In each group, 95% of
cethromycin was bound to plasma proteins. The authors
concluded that no dosage adjustment was necessary in pa-
tients with mild or moderate hepatic impairment.59 Data
are limited in patients with severe hepatic impairment;
cethromycin should be avoided in this population.
Pharmacodynamics
Pharmacodynamic parameters, including Cmax/90%
minimum inhibitory concentration (MIC90), AUC/MIC90,
and percentage of time above MIC90 (%T>MIC90), were
determined for M. pneumoniae, S. pneumoniae, C. pneumo-
niae, M. catarrhalis, and H. influenzae. High intrapulmonary
Cmax/MIC and AUC/MIC90 ratios, high intrapulmonary drug
exposure values, and prolonged %T>MIC90 were found for
all organisms except H. influenzae. The authors suggested
that a higher daily dose would be necessary to exceed the
MIC90 for H. influenzae in the lungs.54 A murine pneumonia
model that investigated pharmacodynamic parameters
demonstrated that cethromycin achieved rapid concentration-
dependent bactericidal activity against S. pneumoniae iso-
lates, with variable susceptibilities to macrolides. As with
other macrolides and ketolides, the pharmacodynamic pa-
rameters that most closely predict outcomes are AUCunbound/
MIC and Cmax unbound/MIC.60 One study determined the post-
antibiotic effect (PAE) of cethromycin compared to that of
amoxicillin/clavulanate against clinical isolates of S. pneumo-
niae and H. influenzae. The PAEs of cethromycin and amoxi-
cillin/clavulanate ranged from 2.3 to 6.0 hours and 0 to 2.2
hours against S. pneumoniae and from 2.7 to 9.1 hours and 0
to 0.8 hours against H. influenzae, respectively.61
Animal Studies
INHALATION ANTHRAX
In February 2007, the FDA designated cethromycin as
an orphan drug for the prophylactic treatment of patients
exposed to inhalation anthrax due to B. anthracis.62 In May
2007, Advanced Life Sciences announced positive data
from a study that showed a 30-day course of cethromycin
to be effective in preventing inhalation anthrax infection in
primates. Oral cethromycin 16 mg/kg was 100% protective
against a lethal dose of inhaled anthrax as compared to the
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current standard of care, oral ciprofloxacin, which demon-
strated 90% protection.63 Newer studies involving animals
exposed to a lethal dose of inhaled anthrax showed that a
14-day course of oral cethromycin achieved between 60%
and 100% survival rates after the animals demonstrated
symptoms of anthrax infection.64
TULAREMIA
In September 2009, the FDA designated cethromycin as
an orphan drug for the prophylactic treatment of tularemia
due to F. tularensis.62 In December 2009, Advanced Life
Sciences announced positive data from a pivotal study that
showed a 14-day course of once-daily oral cethromycin to
be effective in preventing tularemia infection in primates.
Oral cethromycin 16 mg/kg, when initiated within 24
hours after exposure to a lethal dose of inhaled tularemia,
was 100% protective as compared to placebo.14
PLAGUE
In September 2009, the FDA designated cethromycin as
an orphan drug for the prophylactic treatment of plague
due to Y. pestis.62 Advanced Life Sciences announced posi-
tive data from a pivotal study that showed a 14-day course
of once-daily oral cethromycin to be effective in prevent-
ing plague infection in primates. Oral cethromycin, at dos-
es up to 64 mg/kg initiated 24 hours after exposure to a
lethal dose of inhaled plague, had a 90% survival rate as
compared to placebo.15 Recently, another study was done
on Y. pestis–infected rats to evaluate the dose-related re-
sponse to cethromycin. Rats were given 140 mg/kg/day
orally in 2 divided doses every 24 hours after infection
with Y. pestis for 7 days. Levofloxacin 20 mg/kg/dose was
used as a positive control. Complete protection against
mortality without any toxic effects was noted in the
cethromycin group. Furthermore, blood and spleen cul-
tures performed after treatment detected no plague bacilli.
All survivors were rechallenged with 2 lethal doses of Y.
pestis and did not require additional antibiotic treatment
due to the development of specific antibodies against the V
antigens of Y. pestis. These data demonstrate that
cethromycin is potent treatment for pneumonic plague.65 In
November 2010, Advanced Life Sciences submitted a full
proposal to the National Institute of Allergy and Infectious
Diseases for the development of an intravenous formula-
tion of cethromycin as a biodefense countermeasure.66
Clinical Efficacy: Phase 2 and 3 Trials
COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA
A randomized, parallel-group, double-blind, multicenter
Phase 2 study (N = 182) compared the safety and efficacy
of a 7-day course of orally administered cethromycin 300
mg to that of cethromycin 600 mg for the treatment of
CAP.67 Both doses were effective in achieving clinical cure
(84% vs 73%, respectively) and microbiologic cure (85 % vs
75%, respectively); however, p values were not provided.27
The study supported the selection of once-daily cethromycin
300 mg for the treatment of CAP, as fewer gastrointestinal
adverse events were observed.67 A randomized, parallel-
group, multicenter Phase 2-3 study (N = 583) compared the
efficacy and safety of a 10-day course of therapy with that of
cethromycin 150 mg once daily versus cethromycin 150 mg
twice daily in ambulatory subjects with CAP.27,68 Both doses
were safe and well tolerated. Equivalence in the clinical cure
rates (83% vs 81%), overall bacteriologic cure rates (83% vs
82%) (p values not provided), and pathogen eradication rates
were demonstrated in the intent-to-treat population. Higher
clinical cure rates in the clinically evaluable and clinically
and bacteriologically evaluable populations were observed in
the 150-mg once-daily treatment arm. A randomized, paral-
lel-group, multicenter study (N = 582) compared a 7-day
course of therapy of cethromycin 300 mg once daily versus
cethromycin 250 mg twice daily in subjects with CAP.69
Clinical cure rates were 83% versus 81%, respectively, and
bacteriologic cure rates were 90% versus 86%, respectively
(p values not provided). Results from these studies, combined
with the pharmacokinetics/pharmacodynamics results from
other studies, support a clinical dose selection for CAP treat-
ment of 300 mg daily of cethromycin for 7 days. Two Phase
3 prospective, double-blind, randomized, parallel-group,
multicenter, multinational, noninferiority studies (CL05-001
and CL06-001) evaluated the safety and efficacy of a 7-day
course of oral cethromycin 300 mg daily versus oral clar-
ithromycin 250 mg twice daily in patients with mild to mod-
erate CAP.17 CL05-001 and CL06-001 demonstrated nonin-
ferior cure rates at the visit 4 test-of-cure in the cethromycin
group compared to the clarithromycin group in both the in-
tent-to-treat analysis (CL05-001: 83.1% vs 81.1% [95% CI
– 4.8% to 8.9%], CL06-001: 82.9% vs 88.5% [95% CI
–11.9% to 0.6%]) and the per protocol clinical population
(CL05-001: 94% vs 93.8% [95% CI –4.5% to 5.1%], CL06-
001: 91.5% vs 95.9% [95% CI –9.1% to 0.3%]). No clinical-
ly significant adverse events were observed during the stud-
ies. Cethromycin may be potential oral therapy for the outpa-
tient treatment of CAP.
ACUTE BACTERIAL SINUSITIS
A Phase 2 double-blind, randomized, parallel-group,
multicenter study compared the safety and efficacy of 10-
day oral courses of cethromycin 150 mg daily, cethromy-
cin 300 mg daily, and cethromycin 600 mg daily for the
treatment of acute bacterial sinusitis (ABS).70 The clinical
and bacteriologic cure rates were generally greater in the
300-mg daily group. Approximately 300 subjects were en-
rolled, and the study found that clinical and radiographic
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response rates were generally lower for patients taking 600
mg of cethromycin daily, possibly because they exhibited a
statistically significant increase in the number of gastroin-
testinal adverse events, making them somewhat less adher-
ent to their treatment regimen. As a result, the overall path-
ogen cure rate was significantly higher (p < 0.05) in the
300-mg group than in the 600-mg group. 
A Phase 2-3 study compared the safety and efficacy of a
10-day course of oral cethromycin 150 mg once daily to
that of oral cethromycin 150 mg twice daily for the treat-
ment of ABS.70 The study enrolled more than 600 patients
and demonstrated that both treatment regimens were effec-
tive in resolving or improving clinical signs and symptoms
of ABS and eradicating the target pathogens in the adults.70
This study, combined with previous clinical trials for CAP
and acute bacterial exacerbation of chronic bronchitis, sup-
ports the selection of a 300-mg daily dosing regimen in
further studies of cethromycin in treating ABS.
ACUTE BACTERIAL EXACERBATION OF CHRONIC
BRONCHITIS
A randomized, double-blind, multicenter, parallel-group
Phase 2 study compared the efficacy and safety of once-daily
cethromycin 150 mg, 300 mg, and 600 mg given orally for 5
days in patients with acute bacterial exacerbation of chronic
bronchitis (ABECB).71 Clinical cure rates with cethromycin
in the clinically evaluable patients were 87% (150 mg), 90%
(300 mg), and 90% (600 mg). The bacteriologic cure rates in
the clinically evaluable patients were 86% (150 mg), 88%
(300 mg), and 92% (600 mg) (p values not provided). Lower
efficacy was observed with the 150-mg dose and an in-
creased incidence of gastrointestinal adverse effects was ob-
served with the 600-mg dose. A randomized, double-blind,
multicenter, parallel-group Phase 3 study showed the efficacy
of both a 5-day once-daily course of oral cethromycin 150
mg and a 7-day once-daily course of oral levofloxacin 500
mg, in ambulatory males and females older than 40 years
with ABECB.72 The study did not establish noninferiority of
cethromycin, suggesting a dose of 300 mg may be more ap-
propriate in comparator clinical studies of cethromycin ver-
sus standard-of-care therapy in ABECB.
Safety/Adverse Effects
Data on adverse effects are limited, but suggest that
cethromycin is safe and well tolerated. Adverse effects ap-
pear to be dose-related, with gastrointestinal (diarrhea, nau-
sea, vomiting, and abdominal pain) and nervous system
(headaches) disorders as the most prominent. The overall
incidence of treatment-emergent adverse effects is propor-
tional to the frequency of drug administration and notably
higher with the once-daily regimen compared to the twice-
daily or 3-times-daily regimens.8 In Phase 2 CAP trials, the
rate of serious adverse events and drug discontinuation due to
these events was very low, ranging from 0 to 6.2%.67,68 The
most common adverse effects were gastrointestinal, affecting
18% of patients receiving 150 mg once daily, 27% receiving
300 mg once daily, and 49% receiving 600 mg once daily.
Similar safety results were observed in Phase 2 and Phase 3
ABECB trials.71,72 Unlike with telithromycin, no cases of se-
vere hepatotoxicity were detected. In a recent Phase 3 CAP
trial, dysgeusia was significantly reported in patients receiv-
ing cethromycin 300 mg daily compared to clarithromycin
250 mg twice daily (4.0% vs 9.3%, p = 0.001), but it did not
impact adherence or withdrawal from the study.17
A double-blind, randomized, parallel design study
demonstrated that cethromycin therapeutic (300 mg once
daily for 5 days) and supratherapeutic (900 mg once daily
for 5 days) doses showed a nonsignificant prolongation of
the QTc interval compared to placebo or moxifloxacin in
healthy volunteers.73 There had been no reports of serious
hepatotoxicity, exacerbation of myasthenia gravis, or ele-
vated bilirubin at the time of this writing. However, as with
any investigational agent, continued diligence is warranted.
Drug Interactions
Preliminary in vitro data suggest that cethromycin is a
substrate and inhibitor of CYP3A and a substrate and an in-
hibitor of P-glycoprotein.8 Coadministration of rifampin, a
potent CYP3A4 inducer, reduced the cethromycin Cmax by
92% and the AUC by 95%, suggesting that cethromycin
should not be used with potent CYP3A inducers. Coadminis-
tration of ketoconazole, a potent CYP3A4 inhibitor, in-
creased the mean cethromycin Cmax 2.6-fold and its AUC
4.9-fold, suggesting a need for cethromycin dose adjustment
when administered with potent CYP3A inhibitors. Coadmin-
istration with midazolam, a CYP3A substrate, increased the
mean midazolam Cmax 1.5-fold and its AUC 2.3-fold, sug-
gesting a need for midazolam dose adjustment.8 One study
showed that the administration of ranitidine in healthy volun-
teers 1 hour prior to cethromycin significantly prolonged the
t1/2 of cethromycin by approximately 10%, extended the tmax
by 14%, reduced the Cmax by 25.7%, and reduced the AUC
by 15.8%. The effect of ranitidine might result from the de-
creased solubility of cethromycin at higher gastric pH lev-
els.55 However, the 1-hour prior administration of sucralfate
did not significantly affect the bioavailability of cethromycin.
Another double-blind crossover study showed that concomi-
tant oral administration of cethromycin and theophylline was
well tolerated in healthy volunteers and cethromycin did not
significantly increase the theophylline Cmax, Cmin, or AUC.74
Continued plasma concentration monitoring is recommended
when theophylline, warfarin, and digoxin are coadministered
with cethromycin. Awaiting further evidence, electrocardio-
gram monitoring may also be warranted with concomitant
use of drugs that prolong the QT interval.
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Dosage/Administration
Several cethromycin doses have been studied for the
treatment of CAP, ranging from 150 mg to 600 mg once
daily.71 Clinical cure and safety profile, in addition to phar-
macokinetic data, favored 300-mg once-daily dosing.67-70
An Advanced Life Sciences pivotal study showed that
cethromycin doses up to 64 mg/kg achieved 90% cure
rates for plague in primates15; however, a more recent
study showed that doses up to 140 mg/kg/day are needed
to be effective.65 Doses of 16 mg/kg, which are equivalent
to 300 mg/day in humans, are recommended for anthrax
and tularemia prophylactic treatment.14,15,64
Dosage adjustments for patients with mild to moderate re-
nal impairment or those undergoing dialysis have not been
recommended for cethromycin.8,29 However, Heine et al. rec-
ommend dose adjustment of 150 mg daily for individuals
with estimated creatinine clearance between 10 and 29
mL/min.29 Based on pharmacokinetic studies, no dose adjust-
ments are needed in patients with any degree of hepatic im-
pairment.29
Summary
Cethromycin, a novel ketolide, was shown to be safe
and effective in the treatment of mild to moderate CAP. It
possesses reliable activity against the bacteria most com-
monly associated with CAP including S. pneumoniae, H.
influenzae, M. catarrhalis, M. pneumoniae, C. pneumoniae,
and L. pneumophila. Unlike fluoroquinolones, cethromy-
cin has a narrower spectrum of activity against gram-nega-
tive bacteria, which may reduce the risk of collateral dam-
age and the incidence of Clostridium difficile infection. It
offers an advantage over telithromycin in that hepatotoxici-
ty does not seem to be a concern. The FDA denied ap-
proval of cethromycin for the treatment of CAP in 2009,
requesting more efficacy data. However, a recent trial
showed cethromycin to be noninferior to clarithromycin
for the treatment of mild to moderate pneumonia. Thus, if
further evaluated and approved by the FDA, cethromycin
may represent an attractive therapeutic option for the treat-
ment of mild to moderate CABP. In addition, cethromycin
has been designated by the FDA as an orphan drug for pro-
phylactic treatment of anthrax inhalation, tularemia, and
plague and may represent a valuable addition to the arma-
mentarium of antibiotics directed against bioterrorism.
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OBJETIVO: Revisar la farmacología, química, microbiología, susceptibili-
dad in vitro, mecanismo de resistencia, farmacocinética, farmacodiná-
mica, eficacia clínica, seguridad, interacciones con otros fármacos, dosifi-
cación y administración de cetromicina, un nuevo antibiótico quetólido.
FUENTES DE INFORMACIÓN: Se obtuvo la literatura a través de una
búsqueda de PubMed (1950-octubre 2012), International
Pharmaceutical Abstracts (1970-octubre 2012), y una revisión
bibliográfica de los artículos publicados. Los términos de búsqueda
incluyeron cetromicina, ABT-773, antibiótico quetólido, y pulmonía
adquirida en comunidad.
SELECCIÓN Y EXTRACCIÓN DE FUENTES DE INFORMACIÓN: Todos los
estudios in vitro y preclínicos disponibles, así como estudios clínicos
Fase I, II y II publicados en inglés fueron evaluados para resumir la
farmacología, química, microbiología, eficacia, y seguridad de
cetromicina en el tratamiento de infecciones del trayecto respiratorio.
SÍNTESIS: Cetromicina, un nuevo quetólido, tiene un mecanismo de
acción similar a telitromicina con un perfil de seguridad aparentemente
mejor. Presenta una actividad in vitro contra bacterias selectas gram-
positivas, gram-negativas y atípicas. La indicación propuesta para
cetromicina es el tratamiento de pulmonía bacteriana leve a moderada
adquirida en la comunidad en pacientes de 18 años o más. Según los
estudios clínicos, la dosis recomendada es 300 mg por vía oral una vez
al día con o sin comidas. Cetromicina ha sido designada como fármaco
huérfano para la prevención de tularemia, plaga y ántrax. Aunque la
Administración de Alimentos y Drogas de los Estados Unidos (FDA) en
2009 no aprobó su uso en el tratamiento de pulmonía adquirida en
comunidad, un estudio reciente de no-inferioridad demostró una eficacia
comparable a claritromicina. Información preliminar sobre sus efectos
adversos sugieren que cetromicina es segura y que sus efectos adversos
gastrointestinales aparentan ser relacionado a la dosis.
CONCLUSIONES: Cetromicina aparenta ser un quetólido prometedor para
el tratamiento de pulmonía leve a moderada adquirida en comunidad. La
FDA denegó su aprobación en 2009 pendiente a más evidencia que
demuestre su eficacia. Estudios más recientes demuestran que no es
inferior a otros antibióticos para la misma indicación.
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OBJECTIF: Revoir la pharmacologie, la chimie, la microbiologie,
l’activité in vitro, les mécanismes de résistance, la pharmacocinétique, la
pharmacodynamique, l’efficacité clinique, l’innocuité, les interactions
médicamenteuses, et la posologie de la céthromycine, un nouvel
antibiotique de la classe des kétolides. 
PROVENANCE DES DONNÉES: Les publications ont été identifiées à l’aide
d’une recherche informatisée des banques de données PubMed
(1950– octobre 2012) et International Pharmaceutical Abstracts
(1970–octobre 2012), de même que de la revue de la bibliographie des
publications identifiées. Les termes utilisés pour la recherche incluaient
céthromycine, ABT-773, antibiotique kétolide, et pneumonie extra-
hospitalière. 
SÉLECTION DES DONNÉES: Toutes les études disponibles qu’elles soient
précliniques, in vitro, de phase I, II ou III publiées en langue anglaise ont
été évaluées et résumées. 
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RÉSUMÉ: La céthromycine, un nouvel antibiotique de la classe des
kétolides, possède un mécanisme d’action similaire à la télithromycine,
avec apparemment, un profil d’innocuité plus favorable. Elle est active
in vitro contre les bactéries gram-positif, les bactéries gram-négatif et les
bactéries atypiques. La céthromycine est proposée pour le traitement des
pneumonies extra-hospitalières d’intensité légère à modérée chez les
adultes de 18 ans et plus. Pour cette indication, la dose recommandée
serait de 300 mg une fois par jour sans égard à la prise d’aliments. En
2009, la FDA des États-Unis d’Amérique a rejeté la soumission du
fabriquant et demandé des évidences supplémentaires. La céthromycine
a cependant obtenu le statut de médicament orphelin pour le traitement
de la tularémie, de la peste et en prophylaxie lors d’exposition à
l’anthrax. Depuis lors, une étude contrôlée et à répartition aléatoire a
démontré une efficacité non-inférieure à celle de la clarithromycine et
des données préliminaires suggèrent un profil d’innocuité acceptable et
des effets gastro-intestinaux associés à la dose. 
CONCLUSIONS: La céthromycine apparait prometteuse comme antibiotique
de la classe des kétolides pour traiter les pneumonies extra-hospitalières
d’intensité légère à modérée. Après un premier rejet en 2009 de la part
de la FDA des États-Unis d’Amérique, des données plus récentes
soutiennent une efficacité non-inférieure de la céthromycine à celles des
autres antibiotiques de cette classe. 
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